[CAS NO. 315694-89-4] TC-DAPK6
PRODUCTS SPECIFICATIONS [315694-89-4]
DESCRIPTION [315694-89-4]
Overview
| MDL | MFCD07278745 |
|---|---|
| Molecular Weight | 276.29 |
| Molecular Formula | C17H12N2O2 |
| SMILES | O=C(OC(/C=C/C1=CC=CC=C1)=N/2)C2=C/C3=CC=CN=C3 |
9 Publications Citing Use of MCE
- [1]Biol Psychiatry. 2019 May 1;85(9):769-781.
- [2]Theranostics. 2022 May 9;12(8):3847-3861.
- [3]Theranostics. 2020 Sep 15;10(25):11479-11496.
- [4]Cancer Sci. 2020 May 24;111(8):2803-2813.
- [5]Exp Neurol. 2020 Jul;329:113303.
- [6]J Mol Med-JMM. 2019 Jan;97(1):89-102.
- [7]Lab Invest. 2019 Jul;99(8):1143-1156.
- [8]Sci Rep. 2018 Jul 2;8(1):9930.
- [9]Dis Markers. 17 Jan 2022.
Summary
TC-DAPK 6 is a potent, ATP-competitive, and highly selective DAPK inhibitor ( IC 50 =69 and 225 nM against DAPK1 and DAPK3 , respectively, with 10 μM ATP).
IC50 & Target
IC50: 69 nM (DAPK1), 225 nM (DAPK3) [1]
In Vitro
TC-DAPK 6 is found to be the most potent Death-associated protein kinase (DAPK) inhibitor with enzyme selectivity. When assayed with 10 μM ATP, the IC 50 values for DAPK1 and DAPK3 are 69 and 225 nM, respectively. TC-DAPK 6 also inhibits p70S6K (1 μM < IC 50 < 10 μM) [1] .
MCE has not independently confirmed the accuracy of these methods. They are for reference only.
Appearance
Solid
Shipping
Room temperature in continental US; may vary elsewhere.
Storage
| Powder | -20°C | 3 years |
|---|---|---|
| 4°C | 2 years | |
| In solvent | -80°C | 6 months |
| -20°C | 1 month |
Solvent & Solubility
DMSO : 18.67 mg/mL ( 67.57 mM ; Need ultrasonic and warming)
Stock Solutions
| Concentration Solvent Mass | 1 mg | 5 mg | 10 mg |
|---|
| 1 mM | 3.6194 mL | 18.0969 mL | 36.1939 mL |
| 5 mM | 0.7239 mL | 3.6194 mL | 7.2388 mL |
| 10 mM | 0.3619 mL | 1.8097 mL | 3.6194 mL |
-
1.
Add each solvent one by one: 10% DMSO >> 90% (20% SBE-β-CD in saline)
Solubility: 2 mg/mL (7.24 mM); Suspended solution; Need ultrasonic